Suppr超能文献

协调性心脏肥大和血管生成的破坏促成了向心力衰竭的转变。

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

作者信息

Shiojima Ichiro, Sato Kaori, Izumiya Yasuhiro, Schiekofer Stephan, Ito Masahiro, Liao Ronglih, Colucci Wilson S, Walsh Kenneth

机构信息

Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA.

出版信息

J Clin Invest. 2005 Aug;115(8):2108-18. doi: 10.1172/JCI24682.

Abstract

Although increased external load initially induces cardiac hypertrophy with preserved contractility, sustained overload eventually leads to heart failure through poorly understood mechanisms. Here we describe a conditional transgenic system in mice characterized by the sequential development of adaptive cardiac hypertrophy with preserved contractility in the acute phase and dilated cardiomyopathy in the chronic phase following the induction of an activated Akt1 gene in the heart. Coronary angiogenesis was enhanced during the acute phase of adaptive cardiac growth but reduced as hearts underwent pathological remodeling. Enhanced angiogenesis in the acute phase was associated with mammalian target of rapamycin-dependent induction of myocardial VEGF and angiopoietin-2 expression. Inhibition of angiogenesis by a decoy VEGF receptor in the acute phase led to decreased capillary density, contractile dysfunction, and impaired cardiac growth. Thus, both heart size and cardiac function are angiogenesis dependent, and disruption of coordinated tissue growth and angiogenesis in the heart contributes to the progression from adaptive cardiac hypertrophy to heart failure.

摘要

尽管增加的外部负荷最初会诱导心脏肥大且收缩力保持不变,但持续的超负荷最终会通过尚不清楚的机制导致心力衰竭。在此,我们描述了一种小鼠条件转基因系统,其特征是在心脏中诱导激活的Akt1基因后,急性期出现适应性心脏肥大且收缩力保持不变,慢性期则发展为扩张型心肌病。在适应性心脏生长的急性期,冠状动脉血管生成增强,但随着心脏发生病理重塑而减少。急性期血管生成增强与雷帕霉素哺乳动物靶标依赖性诱导心肌VEGF和血管生成素-2表达有关。在急性期用诱饵VEGF受体抑制血管生成会导致毛细血管密度降低、收缩功能障碍和心脏生长受损。因此,心脏大小和心脏功能均依赖于血管生成,心脏中协调的组织生长和血管生成的破坏有助于从适应性心脏肥大发展为心力衰竭。

相似文献

3
Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy.
J Mol Cell Cardiol. 2005 Feb;38(2):375-85. doi: 10.1016/j.yjmcc.2004.12.002. Epub 2005 Jan 25.
6
Distinct functions of junD in cardiac hypertrophy and heart failure.
Genes Dev. 2005 Jan 15;19(2):208-13. doi: 10.1101/gad.327005.
7
The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure.
Circ Res. 2003 May 2;92(8):912-9. doi: 10.1161/01.RES.0000069686.31472.C5. Epub 2003 Apr 3.
10
Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload.
Circ Res. 2005 May 27;96(10):1087-94. doi: 10.1161/01.RES.0000168028.36081.e0. Epub 2005 Apr 28.

引用本文的文献

1
Transcriptional meta-analysis and immune cell profiles reveal altered neutrophil dynamics in chronic atrial fibrillation.
R Soc Open Sci. 2025 Mar 5;12(3):241102. doi: 10.1098/rsos.241102. eCollection 2025 Mar.
2
Novel model of cardiac hypertrophy with cardiorenal dysfunction.
Sci Rep. 2025 Jul 19;15(1):26242. doi: 10.1038/s41598-025-90435-z.
3
Semaphorin 3F is elevated in serum of heart failure patients and inhibits cardiac angiogenesis via the VEGF/Akt/eNOS pathway.
J Mol Cell Cardiol Plus. 2025 Jun 25;13:100470. doi: 10.1016/j.jmccpl.2025.100470. eCollection 2025 Sep.
5
Molecular Mechanisms of Type 2 Diabetes-Related Heart Disease and Therapeutic Insights.
Int J Mol Sci. 2025 May 9;26(10):4548. doi: 10.3390/ijms26104548.
6
A biodegradable, microstructured, electroconductive and nano-integrated drug eluting patch (MENDEP) for myocardial tissue engineering.
Bioact Mater. 2025 Apr 14;50:246-272. doi: 10.1016/j.bioactmat.2025.04.008. eCollection 2025 Aug.
7
Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer.
iScience. 2025 Jan 4;28(4):111759. doi: 10.1016/j.isci.2025.111759. eCollection 2025 Apr 18.
8
Enhancement of mitochondrial calcium uptake is cardioprotective against maladaptive hypertrophy by retrograde signaling uptuning Akt.
Proc Natl Acad Sci U S A. 2025 Mar 18;122(11):e2402639122. doi: 10.1073/pnas.2402639122. Epub 2025 Mar 11.

本文引用的文献

1
The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling.
J Biol Chem. 2005 May 27;280(21):20814-23. doi: 10.1074/jbc.M500528200. Epub 2005 Mar 21.
2
Loaded wheel running and muscle adaptation in the mouse.
Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H455-65. doi: 10.1152/ajpheart.00085.2005. Epub 2005 Feb 25.
3
Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy.
J Mol Cell Cardiol. 2005 Feb;38(2):375-85. doi: 10.1016/j.yjmcc.2004.12.002. Epub 2005 Jan 25.
4
Genentech discloses safety concerns over Avastin.
Nat Biotechnol. 2004 Oct;22(10):1198. doi: 10.1038/nbt1004-1198.
5
Sex modifies exercise and cardiac adaptation in mice.
Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2768-76. doi: 10.1152/ajpheart.00292.2004. Epub 2004 Aug 19.
7
Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload.
Circulation. 2004 Jun 22;109(24):3050-5. doi: 10.1161/01.CIR.0000130641.08705.45. Epub 2004 Jun 7.
8
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Nat Rev Drug Discov. 2004 May;3(5):391-400. doi: 10.1038/nrd1381.
9
Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes.
Circ Res. 2004 Apr 16;94(7):884-91. doi: 10.1161/01.RES.0000124394.01180.BE. Epub 2004 Feb 26.
10
TOR signaling.
Sci STKE. 2003 Dec 9;2003(212):re15. doi: 10.1126/stke.2122003re15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验